The $40 Cure They Don't Want You to Know About
In this podcast, I sit down with Dr. Jon Berner to explore two of the most promising yet misunderstood therapeutic agents: Lithium and Rapamycin.
We begin with a groundbreaking discussion on Lithium, moving far beyond its traditional use in psychiatry. We break down the recent landmark study in Nature that positions lithium as a potential powerhouse for combating Alzheimer's disease, delve into the different salts (orotate vs. carbonate), and discuss who might benefit, who should be cautious, and the practical realities of dosing and side effects.
In the second half, we shifted to Rapamycin, focusing on an exciting new preprint study on its use for Chronic Fatigue Syndrome (ME/CFS). We explore the compelling "hyperinflammatory" hypothesis for ME/CFS and long COVID, question whether current off-label dosing is too low, and debate the classic mTORC1 vs. mTORC2 model. The conversation also covers radical new ideas like high-dose pulse therapy, its potential use in IVF, and the powerful synergy of combining rapamycin with ketamine for treatment-resistant conditions.
Throughout, we tackle the larger themes of personalized medicine, the limitations of the FDA, and how new AI-driven tools are beginning to map the complex, N-dimensional biochemical space of human health.
Weitere Episoden von „The Optispan Podcast with Matt Kaeberlein“
Verpasse keine Episode von “The Optispan Podcast with Matt Kaeberlein” und abonniere ihn in der kostenlosen GetPodcast App.
